ACTU Stock Analysis: Buy, Sell, or Hold?
ACTU - Actuate Therapeutics, Inc. Common stock
$1.82
-0.06 (-3.19%)
▼
5d:
-13.74%
30d:
-38.31%
90d:
-40.33%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When ACTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ACTU is down 13.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ACTU is down 13.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACTU is currently trading at $1.82, which is considered oversold relative to its 30-day fair value range of $2.19 to $3.06.
Technical Outlook: Technically, ACTU is in a strong downtrend. The price is currently testing key support at $1.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.98 (+448.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACTU is in a strong downtrend. The price is currently testing key support at $1.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.98 (+448.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.19 -
$3.06
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 448.2% below Wall St target ($9.98)
- WARNING: Recommendation downgraded due to -13.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.19 -
$3.06
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.82
Resistance Level
$2.79
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.14
Wall Street Target
$9.98
(+448.2%)
Share & Embed Analysis
Last updated: June 03, 2026 10:44 PM ET
Data refreshes hourly during market hours. Next update: 11:44 PM
Data refreshes hourly during market hours. Next update: 11:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Todd S Thomson
SELL
280000 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 66 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 55 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 53 HOLD |
